Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Current Pharmaceutical Biotechnology 2020-Jan

Icariin stimulates hFOB 1.19 osteoblast proliferation and differentiation via OPG/RANKL mediated by the estrogen receptor.

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Krækjan er vistuð á klemmuspjaldið
Lin-Jun Sun
Chong Li
Xiang-Hao Wen
Lu Guo
Zi-Fen Guo
Lan-Qing Liao
Yu Guo

Lykilorð

Útdráttur

Icariin (ICA), is one of the main effective components isolated from the traditional Chinese herb Epimedium brevicornu Maxim, has been reported to possess extensive pharmacological actions, including enhanced sexual function, immune regulation, anti-inflammation, and anti-osteoporosis. Our study was designed to investigate the effect of ICA on cell proliferation and differentiation and the molecular mechanism of OPG/RANKL mediated by the estrogen receptor (ER) in hFOB1.19 human osteoblast cells. The experimental results show that ICA can stimulate cell proliferation and increase the activity of alkaline phosphatase (ALP), osteocalcin (BGP) and I collagen (Col I) and the amount of calcified nodules. Furthermore the mRNA and protein expression of OPG and RANKL and the OPG/RANKL mRNA and protein expression ratios were upregulated by ICA. The above mentioned results indicated that the optimal concentration of ICA for stimulating osteogenesis was 50 ng/mL. Subsequent mechanistic studies comparing 50 ng/mL ICA with an estrogen receptor antagonist demonstrated that the effect of upregulated expression is connected with the estrogen receptor. In conclusions, ICA can regulate bone formation by promoting cell proliferation and differentiation and upregulating the OPG/RANKL expression ratio by the ER in hFOB1.19 human osteoblast cells.

Skráðu þig á
facebook síðu okkar

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

  • Virkar á 55 tungumálum
  • Jurtalækningar studdir af vísindum
  • Jurtaviðurkenning eftir ímynd
  • Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
  • Lestu vísindarit sem tengjast leit þinni
  • Leitaðu að lækningajurtum eftir áhrifum þeirra
  • Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum

Google Play badgeApp Store badge